Cytosorbents Corp — Form 8-K
Filed November 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 24/100
What the filing says
CytoSorbents Corporation issued 556,681 common shares and 151,822 pre-funded warrant shares to institutional investors at ~$6.18 per share on November 19, 2026, plus 96,527 director/officer shares and 202,429 shares to Avenue Capital to satisfy $1M debt. H.C. Wainwright served as placement agent. Pre-funded warrants exercisable at $0.001; proceeds fund ~$3M debt repayment and working capital.
Why this rating
Capital raise ~20% of company value, dilutive but routine; debt reduction positive. Standard registered offering at modest premium typical for small-cap biomedical.
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.